Treatment strategies and metabolic pathway regulation in urothelial cell carcinoma: a comprehensive review

Huang-Yu Yang 1,2,*; Chao-Yi Wu 3; Jia-Jin Chen 4 and Tao-Han, Lee 1,*

1 Department of Nephrology, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan;

2 Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

3 Division of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan; joywucgu@cgmh.org.tw

* Correspondence: hyyang01@gmail.com (H.-Y.Y.) and b9602100@cgmh.org.tw (T.-H. L.)

Abstract: Cisplatin-based chemotherapy has long been viewed as the first-line chemotherapy for advanced and metastatic urothelial carcinoma (UC). However, many patients with UC have been classified as “cisplatin-ineligible patient”, which requires alternative chemotherapy due to their poor responses. In fact, vast majority of those who initially responded to cisplatin-based chemotherapy eventually progressed. Understanding of UC tumor immunology provided an immunopathogenic bases for immune checkpoint inhibitors, targeting PD-1 and CTLA-4, to treat cisplatin ineligible metastatic UC and patients with platinum-refractory metastatic UC. In 2020, data from the trial further showed that PD-L1 inhibitors benefit prolonged survival and progression-free survival as maintenance therapy. Besides immune-targeting therapies, manipulation of tumor microenvironment via metabolic pathways alternation, such as inhibiting tumor glycolysis, lactate accumulation and exogenous glutamine uptake, has been investigated in the past few years. In this comprehensive review, we started by introducing traditional chemotherapy of UC, and summarized current evidences supporting the use of immune checkpoint inhibitors and highlighted ongoing clinical trials. Lastly, we reviewed the tumor metabolic characteristic and the anti-tumor treatments targeting metabolic pathways.

Keywords: Urothelial carcinoma, immune checkpoint inhibitors, immunotherapy, tumor microenvironment, metabolic pathway

1. Epidemiology and pathogenesis of urothelial carcinoma

Bladder cancer is the most common malignancy involving the urinary system and a common malignancy worldwide. The American Cancer Society reported about 80,470 new cases of bladder cancer and about 17,670 deaths due to bladder cancer in 2019 [1]. Among the various histological types of bladder cancers, urothelial carcinoma of the bladder (UCB) is the most common and is referred to as upper tract urothelial carcinoma (UTUC) when its involvement site changes to the renal pelvis and ureter. Although UTUC is less common than UCB, it usually shows more invasive staging at diagnosis. Tobacco smoking is a well-known risk factor for both UCB and UTUC and is responsible for more than 50% of all urothelial carcinomas (UCs). In addition to smoking, aristolochic acid (AA) consumption has been identified as an important environmental risk factor for UCs in the past few
years. AA is a common component in Chinese medicines and some weight loss regimens in Western countries and has been linked to Chinese herbal nephropathy and Balkan endemic nephropathy. It generates AA-derived DNA adducts and is accompanied by a high frequency of A:T pair mutations of the TP53 gene [2-4]. According to a previous molecular epidemiology report, the ratio of UTUC to total UCs is significantly higher in endemic areas and more than half of these UTUC cases are possibly associated with AA exposure [5]. Before the development of effective chemotherapy strategies, UC was a lethal disease, with a median survival of 3–6 months; nearly all patients died from progression to locally advanced cancer or metastatic disease [6]. The survival outcomes of UC were greatly improved since the use of cisplatin-based chemotherapy as first-line therapy for both locally advanced and metastatic UC; however, more than 50% patients were considered ineligible for cisplatin-based chemotherapy due to compromised performance status, renal failure, or heart failure. Most cisplatin-ineligible patients had no choice but to receive alternative regimens that have less efficacy. This situation has changed in the past few years with the use of immune checkpoint inhibitors (ICIs) in the management of UCs. ICIs have shown positive results as first-line treatment in cisplatin-ineligible patients and second-line treatment in patients with platinum-refractory metastatic UC. In this comprehensive review, we have summarized the treatment strategies in UC, including traditional chemotherapy and immunotherapy, and provided new evidence regarding metabolic interventions in the management of malignancies.

2. Chemotherapy in urothelial carcinoma

For non-muscle-invasive UCB (stage Ta, T1, and Tis) or low-risk UTUC, conservative treatment including transurethral resection, kidney-sparing surgery, and intravesical therapy appears to be a rational choice considering the importance of preserving bladder and renal function [7, 8]. However, approximately 25% patients will progress to muscle-invasive disease or develop metastatic disease after initial conservative therapy, leading to the development of second primary tumors along the urothelium in the genitourinary tract, including the renal pelvis, ureters, urethra, and bladder. When the disease progresses to advanced stages or a metastatic phase, systemic chemotherapy becomes the standard approach; cisplatin-based chemotherapy is the initial choice of therapy for such patients. Gemcitabine plus cisplatin (GC) and dose-dense methotrexate with vinblastine, doxorubicin, and cisplatin (M-VAC) are the common chemotherapy regimens for metastatic UC and have shown similar survival benefit, with a median overall survival of approximately 13.8 and 14.8 months, respectively [6, 9, 10]. Although M-VAC therapy has a response rate of 72% for metastatic disease, its high toxicity and low tolerability have been a major concern. Conversely, the GC regimen appears to have a better safety profile and higher tolerability than the M-VAC regimen, but in a previous report, nearly 30% patients experienced anemia and 50% patients developed thrombocytopenia after GC therapy [6, 10, 11]. In 2011, Galsky et al. defined that cisplatin-ineligible patients have one of the following characteristics: Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2, neuropathy grade ≥2 or hearing loss, New York Heart Association Classification III heart failure or higher, or creatinine clearance <60 mL/min [12-16]. Subsequently, this criterion became an important index to evaluate whether cisplatin-based chemotherapy is suitable for patients. However, radical nephroureterectomy with bladder cuff excision with or without template preservation is the standard of care for high-risk UTUC; however, renal function preservation is more challenging in radical nephroureterectomy and patients undergoing this procedure are often unsuitable for cisplatin-based chemotherapy. In a study by Kaag et al., the mean estimated glomerular filtration rate (eGFR) declined significantly after nephroureterectomy; the mean eGFR decreased by 24% compared to the preoperative level. Further, patients eligible for chemotherapy decreased from 49% to 19% after operation using eGFR of 60 mL/min per 1.73 m² as the cutoff value [17].

For cisplatin-ineligible patients, carboplatin-based treatment is considered an alternative; however, carboplatin-based chemotherapy shows disappointing results compared to the cisplatin-based treatment. A study reported that carboplatin-based treatment had a significantly lower percentage of overall response and complete response than cisplatin-based regimen [18, 19]. Considering the poor response showed by alternative chemotherapy regimens in cisplatin-ineligible patients eligible for chemotherapy decreased from 49% to 19% after experiencing anemia and...
patients and a vast majority of cisplatin-eligible patients eventually progress despite objective response in initial cisplatin-based chemotherapy, novel therapy agents had been sought for the treatment of locally advanced and metastatic UC, and ICIs have become the most promising alternative therapy in the past few years.

3. Immunotherapy in urothelial carcinoma

By understanding the immune system and interaction between immune cells and tumor cells, immunotherapy for cancer patients has tremendously expanded in the past decades. In normal physiology, the interaction between antigen-presenting cells (APCs) and T cells is well controlled by a complex and rigorous system, the immune checkpoint system. This system suppresses the adaptive immune response in a timely manner to prevent incorrect or prolonged T cell activation. The co-stimulatory or inhibitory proteins on APCs are key components of the immune checkpoint system that determine the fate of T cells after antigen presentation. For example, when protein CD80/86 on APCs bind to CD28 protein on T cells, a stimulatory response is triggered, leading to T cell proliferation. In contrast, the inhibition cascade is activated when the same protein, CD80/86, binds to the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) or when the programmed death ligand 1 (PD-L1) on APCs binds to programmed death 1 (PD-1) protein on the T cells. Based on the current understanding of cancer immunity, cancer cells may evade the anti-tumor response by exploiting these immune checkpoint pathways and creating a tumor microenvironment (TME) that ultimately impairs immune cell activation and function. ICIs, which have a different effect from the direct cytotoxic effects of traditional chemotherapy, aim to rejuvenate T cell anti-tumor response by using antibodies or recombinant ligands to block malignant cell-induced inhibitory pathways [20-23].

The antagonistic antibodies of CTLA-4 (ipilimumab and tremelimumab) and PD-1 receptor (nivolumab, pembrolizumab, and pidilizumab) or its ligand PD-L1 (atezolizumab, avelumab, and durvalumab) are two classes of ICIs approved by the United States Food and Drug Administration (FDA). Tissue-based assays in various studies suggest that tumors with larger sizes, aggressive behaviors, and poor outcomes are associated with PD-L1 expression [21, 24, 25]. Other studies propose that ICI treatment would be more suitable in malignancies with a high somatic mutation rate because abundant tumor-specific neo-antigens might induce a rigorous immune response post T cell rejuvenation by ICIs. Based on these findings, ICIs appear to be an excellent choice for advanced and metastatic UCs, which not only exhibit aggressive clinical behavior but also are well-known highly antigenic malignancies harboring the fourth highest mutation rate among all cancers [26].

3.1. Immunotherapy: PD-1 signal inhibitor

In 1999, Tasuku Honjo et al. demonstrated that receptor PD-1 is an immune checkpoint based on the finding that PD-1 knockout mice develop autoimmune diseases. The ligands of PD-1, PD-L1 and PD-L2, were identified in 2000 and 2001, respectively. By understanding that tumors can escape host immune surveillance by expressing PD-L1, blocking the PD-1/PD-L1 signaling pathway to improve the outcomes in patients with malignancies seems rational [27-29]. In 2006, the first clinical study using PD-1 signal inhibitor (MDX-1106) against treatment-resistant solid tumors showed improved anti-tumor efficacy and high tolerability [30]. To date, there are nine types of PD-1 signal inhibitors from eight pharmaceutical companies, and more than 500 clinical trials are examining their efficacy in different types of solid and hematological malignancies.

Among these nine types, the FDA has approved two PD-1 signal inhibitors as first-line therapy and five PD-1 signal inhibitors as second-line therapy for locally advanced and metastatic UC. Atezolizumab and pembrolizumab were both approved as first-line therapies for cisplatin-ineligible or platinum-ineligible patients with PD-L1-positive advanced or metastatic UC. Atezolizumab, a humanized engineered immunoglobulin G1 monoclonal antibody that inhibits binding to PD-L1, was first used as first-line treatment for cisplatin-ineligible patients with metastatic UC in the IMVigor210 trial in 2016. Most cisplatin-ineligible patients had renal impairment and low ECOG performance and some had a history of hearing impairment and peripheral neuropathy. In this trial, atezolizumab showed promising response durability and overall survival with low clinically relevant toxicities in
metastatic UC [31]. Almost at the same time, the anti-PD-1 antibody pembrolizumab was investigated for cisplatin-ineligible patients with metastatic UC in the KEYNOTE-052 trial, which showed a 27% complete response rate with acceptable tolerability. The PD-L1 expression level was examined in the KEYNOTE-052 trial, and prolonged median overall survival was observed in patients with PD-L1 combined positive scores ≥10 [32].

Following the failure of platinum-based therapy in patients with advanced or metastatic UC, the FDA approved atezolizumab, avelumab, durvalumab, nivolumab, and pembrolizumab as second-line treatment. IMVigor 210 reported that atezolizumab showed promising results with respect to overall survival and progression-free survival in platinum-refractory metastatic UC, and the result was even better in patients with higher levels of PD-L1 positive immune cells [33]. IMvior211, a phase III clinical trial, compared atezolizumab to the investigator’s choice of therapy (taxanes or vinflunine) for platinum-refractory metastatic UC; despite failing to meet the primary endpoint of the study, the exploratory analysis showed durable response and survival benefits of atezolizumab in the intention to treat population [34]. Furthermore, pembrolizumab was reported to have a prolonged overall survival and lower treatment-related adverse events rate as compared to chemotherapy (paclitaxel, docetaxel, or vinflunine) for platinum-refractory advanced or metastatic UC in the KEYNOTE-045 trial. In this study, pembrolizumab prolonged overall survival regardless of PD-L1 status [35]. Durvalumab, a selective, high-affinity, engineered human monoclonal antibody blocking PD-L1 binding to PD-1, was used in patients with metastatic UC who progressed after the failure of platinum-based chemotherapy in the NCT01693562 clinical trial. In this single-arm phase I/II trial, durvalumab showed favorable results in treatment response rate and overall survival regardless of PD-L1 expression level. Nivolumab, a human monoclonal antibody targeting PD-1, was first reported to have a durable clinical response and manageable safety profile in platinum-refractory advanced or metastatic UC in the CheckMate 032 trial, and significant improvement in overall survival among different PD-L1 expression levels was then observed in the CheckMate 275 study [36, 37]. In the JAVELIN solid tumor study, Avelumab, a human immunoglobulin G1 anti-PD-L1 antibody, showed anti-tumor activity in platinum-refractory or cisplatin ineligible patients, with 40% objective response rate in PD-L1 positive tumor cells in >5% of patients and 9% in PD-L1 positive cells in <5% of patients [38].

Although PD-1 signaling inhibitors showed promising results as monotherapy, a low long-term durable objective response rate and high relapse rate warrants alternative approaches for metastatic UC. Several studies have shown that the cytotoxic effect of chemotherapy might enhance the efficacy of checkpoint inhibitors [39-43]. In IMVigor310, a double-blind phase III trial, combination therapy with atezolizumab plus platinum-based chemotherapy showed significant prolongation of progression-free survival and enhanced interim overall survival and complete response rate [44]. However, another phase III trial, KEYNOTE-361, which compared pembrolizumab with chemotherapy and pembrolizumab alone, failed to meet the primary endpoint, and showed that combination therapy was not superior to pembrolizumab monotherapy with respect to both overall survival and progression-free survival [45]. Currently, ongoing trials are investigating the efficacy of a combination of systemic chemotherapy and checkpoint inhibitors in locally advanced and metastatic UC. Future application of these potential regimens will be determined by the results of these clinical trials.

Besides being the first-line treatment for cisplatin-ineligible or platinum-ineligible metastatic UC and second-line treatment for patients with platinum-refractory metastatic UC, recent reports have revealed that immune checkpoint therapy may also play a role in maintenance therapy. A recently published phase III trial, JAVELIN bladder 100, reported that using avelumab, an anti-PD-L1, as maintenance therapy for patients with locally advanced or metastatic UCB experienced an objective response or stable disease after four to six cycles of GC regimen prolonged overall survival and progression-free survival compared to the best supportive care. This encourages results were observed across all prespecified subgroups regardless of PD-L1 expression status [46, 47]. Based on these data, in 2020, Avelumab was approved by FDA for maintenance therapy in metastatic UC not progressed after initial platinum-based chemotherapy.
Table 1. The indication and therapeutic regimen of programmed death 1 (PD-1) signal inhibitor approved by U.S. Food and Drug Administration (FDA)

<table>
<thead>
<tr>
<th>Indication</th>
<th>PD-1 signal inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-line therapy</td>
<td>cisplatin ineligible or platinum ineligible patients with PD-L1 positive advanced or metastatic UC</td>
</tr>
<tr>
<td>Second line therapy</td>
<td>advanced or metastatic UC following failure platinum-based therapy</td>
</tr>
<tr>
<td>Maintenance therapy</td>
<td>local advanced or metastatic UC with objective response or stable disease after four to six cycle of GC regimen</td>
</tr>
</tbody>
</table>

UC: urothelial carcinoma; GC regimen: Gemcitabine plus cisplatin regimen

3.2. Immunotherapy: CTLA-4 pathway inhibitor

In 1988, CTLA-4 was first recognized as a critical molecule in maintaining T cell homeostasis and tolerance by competing with CD28 for CD80/86 and downregulating T cell receptor (TCR) signaling. The TCR signaling pathway activated by CD28-CD80/86 promotes cytokine interleukin-2 (IL-2) production and leads T cell into the cell cycle entry, T-helper-cell differentiation, and immunoglobulin isotype switching; therefore, CTLA-4 induces T cell anergy by blocking these pathways [48-50]. One theory suggests that the poor immunogenicity of many malignancies may be because these tumors cannot provide a signal strong enough for CD28-mediated co-stimulation, which is necessary to fully activate T cells. Based on this theory, Leach et al. reported that the administration of CTLA-4 antibodies can induce an effective anti-tumor response by blocking the inhibitory effects of CTLA-4 [13, 51, 52]. To date, there are two CTLA-4 inhibitors being examined for their efficacy in various malignancies in several clinical trials.

Tremelimumab, a monoclonal antibody against CTLA-4, has been used as monotherapy for patients with platinum-refractory locally advanced or metastatic UC in the NCT02527434 trial. In this phase II trial, 32 patients with metastatic UC were enrolled and 750 mg tremelimumab was given via intravenous infusion every four weeks for seven cycles and then every 12 weeks for two additional cycles, which resulted in better clinical activity with an objective response rate of 18.8% [53]. There seems to be similar clinical efficacy between CTLA-4 blocking with tremelimumab and PD-1/PD-L1 inhibitor in platinum-refractory UC; however, patients tend to experience more side effects with CTLA-4 inhibition according to the American Association for Cancer Research [54]. Further validation from studies with larger numbers of patients is needed before clinical application.

Considering that ICI targeting the CTLA-4 and PD-1/PD-L1 pathways have distinct mechanisms of T cell response, combination therapies targeting both these pathways to manipulate different phases of immune responses may improve antitumor efficacy.[55-58] Based on this theory, synergistic immunotherapeutic activity of combined inhibition of the CTLA-4 and PD-1/PD-L1 pathways were tested. The CheckMate 032 trial compared nivolumab monotherapy to combination therapy with nivolumab and ipilimumab in platinum-refractory patients, and the combination therapy group was further divided by different ICI dosages. Patients received either 3 mg/kg nivolumab plus 1 mg/kg ipilimumab every three weeks for four doses followed by 3 mg/kg nivolumab monotherapy every two weeks or 1 mg/kg nivolumab plus 3 mg/kg ipilimumab every three weeks for four doses followed by 3 mg/kg nivolumab monotherapy every two weeks. The combination therapy group showed a higher objective response rate to nivolumab monotherapy, and within the combination therapy group, patients who received higher ipilimumab doses showed better objective response rates and complete response rates. No significant toxicities induced by
combination therapy were reported in this study [59]. Based on these results, a phase III trial, CheckMate 901 (NCT03036098), comparing nivolumab with or without ipilimumab with cisplatin or carboplatin-based chemotherapy for metastatic UC in the first-line setting is ongoing. Furthermore, therapy with durvalumab alone or in combination with tremelimumab is being investigated in the NCT02527434 phase II trial for evaluating its safety and efficacy, and durvalumab and tremelimumab combination therapy for patients with stage IV bladder cancer is being investigated in the NCT02516241 phase III trial.

4. Metabolic intervention as cancer treatment

ICIs showed promising clinical activity and durable side effects in locally advanced or metastatic UC, as mentioned above. The overall response rate was still around 30%, according to a previous report [60]. Several studies have revealed a lack of correlation between T cell infiltration in solid tumors, response to immunotherapy, and density of immunogenic antigens, suggesting that there are antigen-independent factors that influence the anti-tumor response [61-64]. Based on the experimental and clinical evidences, the TME might be an antigen-independent factor that influences immune surveillance. TME is characterized by a complex interplay between tumor cells and their surrounding neighbors, including stromal cells, extracellular matrix, adipocytes, and mesenchymal stem cells. TME compromises function and the fate of tumor-infiltrating immune cells by creating a three-dimensional structure favoring immunological tolerance and reducing anti-tumor efficacy even with immunotherapeutic intervention. All the components within TME, including low pH, hypoxia, nutrient-limiting metabolic competition, and nitric oxide (NO) production work together to impair T cell function [20, 65-69].

In 1923, Warburg et al. observed that tumor cells exhibit high glucose uptake and favor glycolysis as energy supplement even with sufficient oxygen, which was coined as the Warburg effect [70-73]. However, glycolysis is also required by T cells, macrophages, and APCs; therefore, competitive TME impairs these immune cells by limiting their glycolytic capacity. Sirtuin 6 (SIRT6), a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, is involved in glucose homeostasis as an epigenetic regulator. SIRT6 deficiency stimulates hypoxia-inducible factor 1α (HIF1α) activity, which increases the expression of glycolysis-related genes, such as lactate dehydrogenase (LDH), glucose transporters (GLUTs), and pyruvate dehydrogenase kinases (PDKs) [74-76]. Several studies have revealed that various human cancers, especially pancreatic and colorectal cancer, are SIRT6 deficient, and restoring SIRT6 activity might be a promising therapeutic strategy in these cases [77-79]. Ellagic acid, a common polyphenol in berries, had been reported to have anti-proliferative effect on human colon adenocarcinoma cells by inhibiting glycolysis via increasing the deacetylase activity of SIRT6 [80-82]. This suggests that targeting SIRT6 activity might be a new insight into the development of anti-cancer therapies. According to the Warburg effect, tumor cells favor glycolysis, which leads to excessive lactate formation even under sufficient oxygen. Lactate, the main metabolite of tumor cells and cancer-associated fibroblasts, is largely accumulated in the TME and has been seen as one of the key components driving immunosuppression and favoring tumor growth [83-86]. Growing evidence indicates that the proton-coupled lactate efflux from cancer cells or stromal cells preserves the acidic phenotype and increases tumor progression by modulating the TME, which

<table>
<thead>
<tr>
<th>Pathway</th>
<th>Mechanism</th>
<th>Drugs</th>
<th>Trial(Phase)/ Experimental model</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune checkpoint inhibitor</td>
<td>blocking PD-L1 and PD-1 interaction</td>
<td>Atezolizumab</td>
<td>NCT02108652 (IMvigor 210, phase II)</td>
<td>FDA-approved first-line and second-line therapy of UC</td>
</tr>
<tr>
<td>PD-1 pathway</td>
<td></td>
<td></td>
<td>NCT02302807 (IMvior211, phase III)</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Clinical trials</td>
<td>FDA approval status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------------------------------</td>
<td>---------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avelumab</td>
<td>NCT01772004 (JAVELIN, phase III)</td>
<td>FDA-approved second-line and maintenance therapy of UC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Durvalumab</td>
<td>NCT01693562 (Study 1108, phase I/II)</td>
<td>FDA-approved second-line therapy of UC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nivolumab</td>
<td>NCT01928394 (CheckMate 032, phase I/II)</td>
<td>FDA-approved second-line therapy of UC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nivolumab</td>
<td>NCT02387996 (CheckMate-275, phase II)</td>
<td>FDA-approved second-line therapy of UC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>NCT02256436 (KEYNOTE-045, phase III)</td>
<td>FDA-approved first-line and second-line therapy of UC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**CTLA-4 pathway**
- blocking CTLA-4 and CD80/86 interaction
- Tremelimumab: NCT02527434 (phase II)
- comparable efficacy as PD-1/PD-L1 inhibitor, but more side effects

**Ipilimumab**
- -
- -

**Combination therapy of PD-1 and CTLA-4 pathway**
- blocking on PD-1 and CTLA-4 pathway
- Nivolumab + Ipilimumab: NCT01928394 (CheckMate 032, phase I/II)
- higher objective response rate to nivolumab monotherapy
- NCT03036098 (CheckMate 901, phase III)
- ongoing

**Metabolic intervention**

<table>
<thead>
<tr>
<th>Pathway</th>
<th>Strategy</th>
<th>Model</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycolysis pathway</td>
<td>inhibit glycolysis via increasing deacetylase activity of SIRT6</td>
<td>Ellagic acid</td>
<td>Cellular model</td>
</tr>
<tr>
<td>Lactate transport and metabolic</td>
<td>inhibit SLC16A1 and SLC16A7</td>
<td>AZ3965</td>
<td>NCT01791595 (phase I)</td>
</tr>
<tr>
<td>LDHA inhibitor</td>
<td>Galloflavin</td>
<td>Cellular model</td>
<td>reduce cancer cells growth and induced apoptosis</td>
</tr>
<tr>
<td>Glutamine transport and metabolic</td>
<td>glutamine antagonist 6-diaz-o-oxo-L-norleucine</td>
<td>Cellular model</td>
<td>anti-tumor effect</td>
</tr>
<tr>
<td>Glutaminase inhibitor</td>
<td>CB-839</td>
<td>NCT03875313 (phase I/II)</td>
<td>Ongoing</td>
</tr>
</tbody>
</table>

FDA: U.S Food and Drug Administration; UC: urothelial carcinoma; LDHA: lactate dehydrogenase A

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 16 October 2020
doi:10.20944/preprints202010.0338.v1

includes cell invasion, angiogenesis, survival signaling, and escaping immune surveillance. An in vitro study reported that human and mouse tumor-specific CD8+ cells reduce cytolytic activity and cytokine production when extracellular pH is lower than 6.0–6.5 [87, 88]. By understanding these mechanisms, molecule targets for lactate transporters, SLC16A1 or SLC16A7, to reduce lactate levels in tumors have been discovered. AZ3965 and α-cyano-4-hydroxycinnamate, small molecules blocking lactate transporters, have been reported to be successful in several types of malignancies including Burkitt lymphoma, breast cancer, small cell lung cancer, and glioblastoma. Another therapeutic approach is to block the conversion of pyruvate to lactate by inhibiting lactate dehydrogenase A (LDHA) [89, 90]. Negative correlation between LDHA expression and T cell activation markers were noted in mice tumor models, and further studies revealed that LDHA...
targeting therapy can re-activate T cell-medicated and natural killer cell mediated immune surveillance [91]. N-hydroxyindole and galloflavin, (LDH) inhibitors, have been shown encourage efficacy on reducing cancer cell growth, and induced apoptosis [92, 93].

In addition to favoring glycolysis, many cancer cells depend on an exogenous supply of glutamine. Glutamine, a non-essential amino acid in mammalian cells, is an important fuel for the tricarboxylic acid cycle, an important source of reduced nitrogen for biosynthesis, and a precursor of nucleotide and lipid synthesis. Although most mammalian cells can synthesize glutamine de novo via glutamine synthetase (GLUL), several types of cancer cells only express low levels of GLUL and need to depend on exogenous glutamine supplementation, which can be catalyzed in the mitochondria via glutaminase [94-97]. Glutamine metabolism is a key component not only for tumor survival but also for regulating the balance between effector T cells and T regulatory cells. Studies have revealed that reduction of glutamine levels in culture media reduced mTORC1 activity and coincided with effector T cell defects, suggesting that the glutamine-depleted TME would suppress anti-tumor immunity [65, 98-101]. In the recent years, by understanding the high demand of glutamine in cancer cells and its regulatory effect on the immune system, the glutamine antagonist 6-diazo-5-oxo-L-norleucine has been re-evaluated as an anti-cancer therapy, especially in glutamine-dependent tumors [102]. Furthermore, CB-839, a potent selective and orally bioavailable inhibitor of glutaminase, showed anti-proliferative activity on tumor cell lines and is being evaluated in clinical trials for the treatment of glutamine-dependent malignancies [103-105]. The metabolic characteristic of dependence on exogenous supplement of glutamine in tumors suggests that surrounding neighbors might play a key role in glutamine supplement. As the cancer grows, they recruit stromal cells as part of the TME; these reactive stromal cells co-evolve and continually interact with cancer cells, becoming an integral part of their physiology and indispensable for their survival. In 2016, Yang et al. identified that reactive stromal cells are reprogrammed through an upregulated glutamine anabolic pathway, which allows them to harness carbon and nitrogen from non-canonical sources to synthesize glutamine in nutrient-deprived TME, and become the exogenous glutamine source for tumor development. In a mouse tumor model, co-targeting glutamine synthetase in stromal cells and glutaminase in cancer cells can reduce tumor size weight and prevent metastasis [95]. These successful findings in animal models or preclinical trials suggest that metabolic crosstalk in the TME may offer a unique opportunity to restore the host’s anti-tumor immunity.

5. Conclusions

We introduce traditional chemotherapy of UC, followed by current evidences supporting the use of immune checkpoint inhibitors and ongoing clinical trials. Moreover, we reviewed the tumor metabolic characteristic and the anti-tumor treatments via metabolic pathways. A better strategy for UC management might be achieved by boosting T cell responses via ICIs and modulating cancer metabolism together. Further research in immunotherapy, including ICIs and immunometabolism intervention, is expected to provide new drug targets that modulate immune cells in a more selective way, providing more potent and less toxic choices for cancer management.

**Funding:** This review article was supported by grants from the Chang Gung Memorial Hospital (CMRPG3F1183).

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

UTUC  Upper tract urothelial carcinoma  
M-VAC  Methotrexate, Vinblastine, Doxorubicin and Cisplatin  
eGFR  Estimated glomerular filtration rate
CTLA-4  Cytotoxic T lymphocyte antigen-4  
LDHA  Lactate dehydrogenase A  
GLUT  Glucose transporters  
GLUL  Glutamine synthetase  
PD-L1  Programmed death ligand 1  
UCB  Urothelial carcinoma of the bladder  
APC  Antigen presenting cell  
PD-1  Programmed death 1  
FDA  Food and Drug Administration  
TME  Tumor microenvironment  
UC  Urothelial carcinoma  
AA  Aristolochic acid  
ICI  Immune checkpoint inhibitor  
GC  Gemcitabine plus cisplatin  
NO  Nitrous oxide

References

42. Seliger, B., Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. Frontiers in Immunology, 2019. 10(999).
45. Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma, in Businesswire. 2020, Pamela Eisele, Kristen Drake


69. Iovanna, J.L. and D. Closa, Factors released by the tumor far microenvironment are decisive for pancreatic adenocarcinoma development and progression. OncoImmunology, 2017. 6(11): p. e1358840.


